Sugi Predict

Sugi Predict / Compounds / SCHEMBL4933283

SCHEMBL4933283

SCHEMBL4933283

CC(C)N1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(Cl)ncn4)cc3)cc2C(F)(F)F)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 6/20 0.69
▸ ABL1 P00519 6/20 0.69
▸ KDR P35968 5/20 0.69
▸ MKNK2 Q9HBH9 4/20 0.69
▸ MKNK1 Q9BUB5 3/20 0.69
▸ FGFR1 P11362 3/20 0.69
▸ RET P07949 3/20 0.69
▸ HCK P08631 3/20 0.69
▸ CDK2 P24941 2/20 0.69
▸ CDK8 P49336 2/20 0.69
▸ AXL P30530 2/20 0.69
▸ FLT3 P36888 2/20 0.69
▸ MERTK Q12866 2/20 0.69
▸ FGFR4 P22455 2/20 0.69
▸ BRAF P15056 2/20 0.69
▸ BCR P11274 2/20 0.69
▸ MAP3K7 O43318 2/20 0.69
▸ FES P07332 2/20 0.69
▸ FER P16591 2/20 0.69
▸ MAP4K2 Q12851 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4936999 0.91 SRC (0.68) SRCABL1KDRMKNK2MKNK1
SCHEMBL4937797 0.91 SRC (0.72) SRCABL1KDRMKNK2MKNK1
SCHEMBL3183607 0.91 SRC (0.82) SRCABL1KDRMKNK2MKNK1
SCHEMBL13991080 0.91 MAPK14 (0.84) SRCABL1KDRMKNK2MKNK1
SCHEMBL13991087 0.90 KDR (0.70) SRCABL1KDRMKNK2MKNK1
SCHEMBL4936158 0.90 KDR (0.70) SRCABL1KDRMKNK2MKNK1
SCHEMBL13991434 0.90 SRC (0.66) SRCABL1KDRMKNK2MKNK1
SCHEMBL4931443 0.89 SRC (0.69) SRCABL1KDRMKNK2MKNK1
SCHEMBL4935112 0.89 SRC (0.69) SRCABL1KDRMKNK2MKNK1
SCHEMBL3166521 0.89 KDR (0.69) SRCABL1KDRMKNK2MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312192-A1 Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases BOLD GUIDO 2008-12-18 — — US claimed
US-20080312192-A1 Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases BOLD GUIDO 2008-12-18 — — US disclosed
US-20080312192-A1 Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases BOLD GUIDO 2008-12-18 — — US disclosed
US-20080312192-A1 Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases BOLD GUIDO 2008-12-18 — — US disclosed
EP-1689376-A2 DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2006-08-16 — — EP disclosed
WO-2005051366-A2 DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2005-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312192-A1 Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases RET, PRKDC, PRKACA SRC 203/4885ABL1 51/4885KDR 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.